SCHEMBL15747728

SCHEMBL15747728

CCC(C)CCC(C(=O)OC)c1cn(C(=O)OC)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 2/20 0.47
CFD P00746 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 6/20 0.37
ALDH1A1 P00352 4/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NR4A2 P43354 1/20 0.36
AKR1C3 P42330 1/20 0.35
CNR1 P21554 2/20 0.35
CNR2 P34972 2/20 0.35
GALR2 O43603 1/20 0.35
MITF O75030 1/20 0.35
GLA P06280 1/20 0.35
HSP90AA1 P07900 1/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15747759 0.85 KMT2A (0.46) KMT2AMEN1CFDL3MBTL1KDM4E
SCHEMBL15747726 0.84 KMT2A (0.49) KMT2AMEN1CFDL3MBTL1KDM4E
SCHEMBL15747731 0.83 KMT2A (0.48) KMT2AMEN1CFDL3MBTL1KDM4E
SCHEMBL17102839 0.82 MEN1 (0.47) KMT2AMEN1CFDKDM4EMAPT
SCHEMBL15747783 0.80 KMT2A (0.45) KMT2AMEN1CFDL3MBTL1KDM4E
SCHEMBL17102854 0.80 KMT2A (0.45) KMT2AMEN1CFDL3MBTL1KDM4E
SCHEMBL15747706 0.79 KMT2A (0.44) KMT2AMEN1CFDL3MBTL1KDM4E
SCHEMBL17102820 0.79 KMT2A (0.57) KMT2AMEN1CFDL3MBTL1KDM4E
SCHEMBL369096 0.77 KMT2A (0.52) KMT2AMEN1L3MBTL1KDM4EALDH1A1
SCHEMBL17102851 0.77 KMT2A (0.49) KMT2AMEN1L3MBTL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11147796-B2 Agent for preventing or ameliorating hearing impairment TOHOKU UNIVERSITY (JP) 2021-10-19 US disclosed
US-11147796-B2 Agent for preventing or ameliorating hearing impairment TOHOKU UNIVERSITY (JP) 2021-10-19 US disclosed
US-10463647-B2 Erythropoietin expression promoter TOHOKU UNIVERSITY (JP) 2019-11-05 US disclosed
US-10463647-B2 Erythropoietin expression promoter TOHOKU UNIVERSITY (JP) 2019-11-05 US disclosed
US-20190224165-A1 Agent for Preventing or Ameliorating Hearing Impairment TOHOKU UNIVERSITY (JP) 2019-07-25 US disclosed
US-20190224165-A1 Agent for Preventing or Ameliorating Hearing Impairment TOHOKU UNIVERSITY (JP) 2019-07-25 US disclosed
US-20180353475-A1 Erythropoietin Expression Promoter KAKE EDUCATIONAL INSTITUTION (JP) 2018-12-13 US disclosed
EP-2923700-B1 ERYTHROPOIETIN EXPRESSION PROMOTER UNIV TOHOKU (JP) 2018-11-07 EP disclosed
US-10004718-B2 Erythropoietin expression promoter TOHOKU UNIVERSITY (JP) 2018-06-26 US disclosed
US-10004718-B2 Erythropoietin expression promoter TOHOKU UNIVERSITY (JP) 2018-06-26 US disclosed
US-10004718-B2 Erythropoietin expression promoter TOHOKU UNIVERSITY (JP) 2018-06-26 US disclosed
US-20150353489-A1 Erythropoietin Expression Promoter KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) 2015-12-10 US disclosed
US-20150353489-A1 Erythropoietin Expression Promoter KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) 2015-12-10 US disclosed
US-20150353489-A1 Erythropoietin Expression Promoter KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) 2015-12-10 US disclosed
EP-2923700-A1 ERYTHROPOIETIN EXPRESSION PROMOTER Tohoku University (JP) 2015-09-30 EP disclosed
WO-2014080640-A1 ERYTHROPOIETIN EXPRESSION PROMOTER 国立大学法人東北大学 (JP) 2014-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180353475-A1 Erythropoietin Expression Promoter EPOR, NFE2L2, FOXO1 KMT2A 3254/4885MEN1 3086/4885CFD 2271/4885
US-11147796-B2 Agent for preventing or ameliorating hearing impairment SLC26A4, OTC, SLC25A20 KMT2A 4378/4885MEN1 1339/4885CFD 3128/4885
US-20150353489-A1 Erythropoietin Expression Promoter EPOR, NFE2L2, FOXO1 KMT2A 3254/4885MEN1 3086/4885CFD 2271/4885
US-20190224165-A1 Agent for Preventing or Ameliorating Hearing Impairment SLC26A4, OTC, SLC25A20 KMT2A 4378/4885MEN1 1339/4885CFD 3128/4885
US-10004718-B2 Erythropoietin expression promoter EPOR, NFE2L2, FOXO1 KMT2A 3254/4885MEN1 3086/4885CFD 2271/4885
US-10463647-B2 Erythropoietin expression promoter EPOR, NFE2L2, FOXO1 KMT2A 3254/4885MEN1 3086/4885CFD 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.